Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01354600
Other study ID # H-2009-0001
Secondary ID
Status Completed
Phase N/A
First received May 5, 2011
Last updated July 22, 2013
Start date May 2009
Est. completion date February 2012

Study information

Verified date July 2013
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to examine the effects of overfeeding and exercise on blood levels of hormones associated with regulating appetite, also thought of as feelings of hunger and satiety (fullness). Previous studies have shown that non-obese people have different amounts of these hormones in their blood compared to obese people.

The investigators hypothesize that exercise will promote improved insulin sensitivity and corresponding beneficial changes in obese individuals. The investigators predict exercise induced changes in 24-hour plasma hormone levels will be associated with improved appetite during overfeeding in obese individuals.


Description:

In a randomized cross-over design, participants will complete two separate six-day & seven night inpatient stays (separated by at least 4 weeks) at the University of Wisconsin Hospital's Clinical and Translational Research Core (CTRC). During each six-day & seven night visit, participants will be fed an energy balance diet (energy intake = energy expenditure) for the first three days followed by three days of overfeeding (130% of the energy balance diet). During one of the inpatient periods, participants will exercise twice daily (once in the morning, once in the evening) for a total of approximately 120 minutes per day on an indoor exercise bicycle at ~50% of maximal aerobic fitness. During the other inpatient visit, participants will not exercise and will be inactive.

The investigators will examine the effect of short-term positive energy balance and exercise on 24-hour plasma levels of hormones related to hunger and satiety. These hormones include leptin, ghrelin, insulin, and peptide YY in sedentary lean and obese men and women. Our primary hypothesis is that when an obese person exercises, average 24-hour plasma leptin levels will increase in obese individuals during overfeeding compared to energy balance feeding, but fail to do so under sedentary conditions. In contrast, the investigators predict lean individuals will have an appropriate increase in average 24-hour leptin levels in response to overfeeding regardless of exercise treatment. Thus, the investigators suggest that a failure in the average 24-hour leptin response to overfeeding sets an obese person up for continued slow weight gain, as the leptin hunger signal fails to detect short-term overfeeding and does not produce a response. The investigators hypothesize that exercise will promote improved insulin sensitivity and increased leptin in the obese. The investigators predict that changes in average 24-hour plasma leptin levels will correlate with self-selected energy intake in lean individuals, but only during overfeeding plus exercise in obese individuals.

In addition, because the hunger and satiety response in humans is complex, this study will characterize the average 24-hour plasma levels of ghrelin, which stimulates hunger, and peptide YY, which stimulate satiety or fullness, in lean and obese individuals to determine if plasma levels are altered in obesity and in response to short-term positive energy balance.

Lastly, this study involves the banking of blood tissue specimens for future research. If it is decided such analysis is of scientific value, genetic analysis will be conducted for alterations in genes involved in the synthesis of, or receptors for, hunger and satiety hormones to be investigated under this study design.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date February 2012
Est. primary completion date November 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria:

- Healthy body mass index (BMI) = 19 < 25 kg/m2

- Obese BMI = 30 < 35 kg/m2

- Activity level = sedentary: Total energy expenditure/resting metabolic rate < 1.6 (average US adult level)

Exclusion Criteria:

- Tobacco use

- Regular exercise or physical activity, defined as > 2h/week of moderate to vigorous activity;

- Individuals who do not eat breakfast

- Weight loss of > 3% of body weight over the previous six months

- Eating a special diet (e.g., vegetarian or low-carbohydrate)

- Current diagnosis of, or using prescription medications for, thyroid dysfunction, type I or type II diabetes, hypertension, cardiovascular, kidney, or liver disease;

- Taking other prescription medications or over-the-country products that alter energy metabolism (other than birth control pills)

- Allergies to any of the foods used in the study

- Individuals who donated blood within 8 weeks prior to enrollment or who plan to give blood during the course of the study

- Claustrophobia

- History of exercise intolerance, including diagnosed exercise induced asthma or any physical limitations to seated cycling aerobic exercise

- Blood chemistries in excess of 130% of the upper normal level and/or hemoglobin or hematocrit below the normal range.

- Females that are pregnant (pregnancy status to be tested at the beginning of each 6-day metabolic chamber stay), lactating, or have irregular menses

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Other:
Exercise or Sedentary
Daily cycling exercise at 50% maximal aerobic fitness for a total of ~120 minutes/day or no daily exercise (sedentary)

Locations

Country Name City State
United States University of Wisconsin Hospitals, Clinical and Translational Research Core (CTRC) Madison Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood plasma appetite hormone concentrations Blood samples will be drawn over 24 hours on the third and sixth day of each inpatient visit. Two separate six day & seven night inpatient visits, separated by at least 4 weeks. No
Secondary Perceived subjective appetite measured by visual analog scales Appetite questionnaires will be filled out hourly as well as every 30 minutes after meals from 8:00am to 11:00pm on the third and sixth day of each inpatient visit. Two separate six day & seven night inpatient visits, separated by at least 4 weeks. No
Secondary Energy intake at a breakfast buffet A breakfast buffet will be served the morning after day 3 and day 6 of each inpatient visit to assess food intake following either energy balance (days 1-3) or overfeeding (days 4-6) with or without daily exercise. Two separate six day inpatient visits, separated by at least 4 weeks. No
See also
  Status Clinical Trial Phase
Completed NCT06146322 - Barley Beta-glucan, Glycemic Control, and Appetite N/A
Completed NCT01900340 - Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans Phase 1
Completed NCT02285907 - Protein Quality on Appetite Control, Reward-driven Eating, & Subsequent Food Intake N/A
Suspended NCT03031132 - The Effects of a High Protein Breakfast on Appetite and Sleep in Young Adults N/A
Completed NCT04876495 - The Effects of Whey, Rice and Potato pRotein isOlates on appeTite rEgulatIoN in Healthy Men N/A
Recruiting NCT03009695 - Transcranial Magnetic Stimulation (TMS) in Obesity N/A
Recruiting NCT02075827 - Metabolic Response to Playing Video Games: Two Arm Trial N/A
Withdrawn NCT01946841 - Specific Enteral Nutrition in Malnourished, Dialysis Patients With Chronic Kidney Disease. Efficacy, Safety, Quality of Life Phase 2
Completed NCT01088841 - Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY Phase 1